GB201603987D0 - Uterine cancer treatments - Google Patents

Uterine cancer treatments

Info

Publication number
GB201603987D0
GB201603987D0 GBGB1603987.7A GB201603987A GB201603987D0 GB 201603987 D0 GB201603987 D0 GB 201603987D0 GB 201603987 A GB201603987 A GB 201603987A GB 201603987 D0 GB201603987 D0 GB 201603987D0
Authority
GB
United Kingdom
Prior art keywords
uterine cancer
cancer treatments
treatments
uterine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603987.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1603987.7A priority Critical patent/GB201603987D0/en
Publication of GB201603987D0 publication Critical patent/GB201603987D0/en
Priority to ES17709931T priority patent/ES3005964T3/es
Priority to JP2018545335A priority patent/JP2019511214A/ja
Priority to CR20210036A priority patent/CR20210036A/es
Priority to KR1020187028243A priority patent/KR102493344B1/ko
Priority to CA3015932A priority patent/CA3015932A1/en
Priority to PH1/2022/551120A priority patent/PH12022551120A1/en
Priority to MX2018010779A priority patent/MX2018010779A/es
Priority to PE2018001580A priority patent/PE20181490A1/es
Priority to BR112018015545-4A priority patent/BR112018015545A2/pt
Priority to SG11201807300PA priority patent/SG11201807300PA/en
Priority to EP17709931.4A priority patent/EP3426281B1/en
Priority to AU2017229149A priority patent/AU2017229149B2/en
Priority to KR1020237002840A priority patent/KR20230019501A/ko
Priority to EP24020331.5A priority patent/EP4491191A3/en
Priority to SG10202008070XA priority patent/SG10202008070XA/en
Priority to MA049295A priority patent/MA49295A/fr
Priority to MYPI2018703020A priority patent/MY189796A/en
Priority to MA43466A priority patent/MA43466A1/fr
Priority to PCT/EP2017/054908 priority patent/WO2017153247A1/en
Priority to CN201780016147.1A priority patent/CN109475596B/zh
Priority to CR20210038A priority patent/CR20210038A/es
Priority to EA201891994A priority patent/EA201891994A1/ru
Priority to CN202410747770.6A priority patent/CN118894905A/zh
Priority to CR20180460A priority patent/CR20180460A/es
Priority to US15/451,167 priority patent/US10138287B2/en
Priority to ARP170100576A priority patent/AR108035A1/es
Priority to TW106107560A priority patent/TWI731945B/zh
Priority to TW109119177A priority patent/TWI771694B/zh
Priority to PH12018501828A priority patent/PH12018501828A1/en
Priority to IL261468A priority patent/IL261468A/en
Priority to CL2018002508A priority patent/CL2018002508A1/es
Priority to MX2022003884A priority patent/MX2022003884A/es
Priority to CONC2018/0010284A priority patent/CO2018010284A2/es
Priority to US16/154,457 priority patent/US10669325B2/en
Priority to US16/178,674 priority patent/US10266581B2/en
Priority to US16/178,672 priority patent/US10239932B2/en
Priority to US16/298,652 priority patent/US20190194289A1/en
Priority to US16/680,634 priority patent/US11390660B2/en
Priority to CL2020001897A priority patent/CL2020001897A1/es
Priority to CL2020001898A priority patent/CL2020001898A1/es
Priority to US17/339,371 priority patent/US12221467B2/en
Priority to US17/345,553 priority patent/US12234276B2/en
Priority to AU2021207620A priority patent/AU2021207620A1/en
Priority to JP2023053020A priority patent/JP2023093483A/ja
Priority to US19/012,311 priority patent/US20250145686A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
GBGB1603987.7A 2016-03-08 2016-03-08 Uterine cancer treatments Ceased GB201603987D0 (en)

Priority Applications (46)

Application Number Priority Date Filing Date Title
GBGB1603987.7A GB201603987D0 (en) 2016-03-08 2016-03-08 Uterine cancer treatments
MA049295A MA49295A (fr) 2016-03-08 2017-03-02 Traitements du cancer de l'utérus
EA201891994A EA201891994A1 (ru) 2016-03-08 2017-03-02 Лечение рака матки
CN202410747770.6A CN118894905A (zh) 2016-03-08 2017-03-02 子宫癌治疗
CR20210036A CR20210036A (es) 2016-03-08 2017-03-02 Tratamiento contra el cáncer de útero
KR1020187028243A KR102493344B1 (ko) 2016-03-08 2017-03-02 자궁암 치료
CA3015932A CA3015932A1 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
PH1/2022/551120A PH12022551120A1 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
MX2018010779A MX2018010779A (es) 2016-03-08 2017-03-02 Tratamientos contra el cancer de utero.
PE2018001580A PE20181490A1 (es) 2016-03-08 2017-03-02 Tratamientos contra el cancer de utero
BR112018015545-4A BR112018015545A2 (pt) 2016-03-08 2017-03-02 tratamentos de câncer do útero
SG11201807300PA SG11201807300PA (en) 2016-03-08 2017-03-02 Uterine cancer treatments
EP17709931.4A EP3426281B1 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
AU2017229149A AU2017229149B2 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
KR1020237002840A KR20230019501A (ko) 2016-03-08 2017-03-02 자궁암 치료
EP24020331.5A EP4491191A3 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
SG10202008070XA SG10202008070XA (en) 2016-03-08 2017-03-02 Uterine cancer treatments
JP2018545335A JP2019511214A (ja) 2016-03-08 2017-03-02 子宮がん治療法
MYPI2018703020A MY189796A (en) 2016-03-08 2017-03-02 Uterine cancer treatments
MA43466A MA43466A1 (fr) 2016-03-08 2017-03-02 Traitements du cancer de l'utérus
PCT/EP2017/054908 WO2017153247A1 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
CN201780016147.1A CN109475596B (zh) 2016-03-08 2017-03-02 子宫癌治疗
CR20210038A CR20210038A (es) 2016-03-08 2017-03-02 TRATAMIENTO CONTRA EL CÁNCER DE ÚTERO (Divisional 2018-0460)
ES17709931T ES3005964T3 (en) 2016-03-08 2017-03-02 Uterine cancer treatments
CR20180460A CR20180460A (es) 2016-03-08 2017-03-02 Tratamiento contra el cáncer de útero
US15/451,167 US10138287B2 (en) 2016-03-08 2017-03-06 Uterine cancer treatments
TW109119177A TWI771694B (zh) 2016-03-08 2017-03-08 子宮癌治療
ARP170100576A AR108035A1 (es) 2016-03-08 2017-03-08 Tratamientos contra el cáncer de útero
TW106107560A TWI731945B (zh) 2016-03-08 2017-03-08 子宮癌治療
PH12018501828A PH12018501828A1 (en) 2016-03-08 2018-08-28 Uterine cancer treatments
IL261468A IL261468A (en) 2016-03-08 2018-08-29 Uterine cancer treatments
CL2018002508A CL2018002508A1 (es) 2016-03-08 2018-09-03 Tratamientos contra el cáncer de útero
MX2022003884A MX2022003884A (es) 2016-03-08 2018-09-06 Tratamientos contra el cancer de utero.
CONC2018/0010284A CO2018010284A2 (es) 2016-03-08 2018-09-26 Tratamientos contra el cáncer de útero
US16/154,457 US10669325B2 (en) 2016-03-08 2018-10-08 Uterine cancer treatments
US16/178,674 US10266581B2 (en) 2016-03-08 2018-11-02 Uterine cancer treatments
US16/178,672 US10239932B2 (en) 2016-03-08 2018-11-02 Uterine cancer treatments
US16/298,652 US20190194289A1 (en) 2016-03-08 2019-03-11 Uterine cancer treatments
US16/680,634 US11390660B2 (en) 2016-03-08 2019-11-12 Uterine cancer treatments
CL2020001897A CL2020001897A1 (es) 2016-03-08 2020-07-20 Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
CL2020001898A CL2020001898A1 (es) 2016-03-08 2020-07-20 Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
US17/339,371 US12221467B2 (en) 2016-03-08 2021-06-04 Uterine cancer treatments
US17/345,553 US12234276B2 (en) 2016-03-08 2021-06-11 Uterine cancer treatments
AU2021207620A AU2021207620A1 (en) 2016-03-08 2021-07-26 Uterine cancer treatments
JP2023053020A JP2023093483A (ja) 2016-03-08 2023-03-29 子宮がん治療法
US19/012,311 US20250145686A1 (en) 2016-03-08 2025-01-07 Uterine cancer treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603987.7A GB201603987D0 (en) 2016-03-08 2016-03-08 Uterine cancer treatments

Publications (1)

Publication Number Publication Date
GB201603987D0 true GB201603987D0 (en) 2016-04-20

Family

ID=55859178

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603987.7A Ceased GB201603987D0 (en) 2016-03-08 2016-03-08 Uterine cancer treatments

Country Status (24)

Country Link
US (9) US10138287B2 (enExample)
EP (2) EP3426281B1 (enExample)
JP (2) JP2019511214A (enExample)
KR (2) KR102493344B1 (enExample)
CN (2) CN109475596B (enExample)
AR (1) AR108035A1 (enExample)
AU (2) AU2017229149B2 (enExample)
BR (1) BR112018015545A2 (enExample)
CA (1) CA3015932A1 (enExample)
CL (3) CL2018002508A1 (enExample)
CO (1) CO2018010284A2 (enExample)
CR (3) CR20210038A (enExample)
EA (1) EA201891994A1 (enExample)
ES (1) ES3005964T3 (enExample)
GB (1) GB201603987D0 (enExample)
IL (1) IL261468A (enExample)
MA (2) MA49295A (enExample)
MX (2) MX2018010779A (enExample)
MY (1) MY189796A (enExample)
PE (1) PE20181490A1 (enExample)
PH (2) PH12022551120A1 (enExample)
SG (2) SG10202008070XA (enExample)
TW (2) TWI771694B (enExample)
WO (1) WO2017153247A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
LT3652215T (lt) 2017-07-14 2021-05-25 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN111684062A (zh) 2018-02-09 2020-09-18 伊玛提克斯美国公司 制造t细胞的方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
ES2991645T3 (es) 2019-06-06 2024-12-04 Immatics Biotechnologies Gmbh Clasificación con contraselección mediante péptidos de secuencia similar
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
CN114908167A (zh) * 2022-05-04 2022-08-16 重庆大学附属肿瘤医院 Svil表达水平检测试剂在制备卵巢癌干性诊断试剂中的应用
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN116024341B (zh) * 2022-11-25 2024-08-30 重庆医科大学 乳腺癌标志物及其应用
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2004503213A (ja) 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001275246B2 (en) 2000-06-05 2006-06-29 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use thereof
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
NZ539226A (en) 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR100739118B1 (ko) * 2005-07-22 2007-07-13 이제호 Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자의 신규한 용도
US20100203505A1 (en) * 2005-08-18 2010-08-12 Eisai R&D Management Co., Ltd. DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CN1920036A (zh) * 2006-03-29 2007-02-28 山东中医药大学 猕猴孕酮受体基因片段及其应用
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PL2562184T3 (pl) 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US9439944B2 (en) * 2008-04-22 2016-09-13 Sungyunkwan University Foundation For Corporate Collaboration Agent that inhibits angiogenesis and metastasis targeting mTOR signaling pathway
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TWI404748B (zh) 2009-11-10 2013-08-11 Enrestec Inc 連續式裂解系統及其應用
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CA2816225A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
NZ609916A (en) * 2010-12-14 2015-03-27 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US9688991B2 (en) * 2012-07-13 2017-06-27 Albert Einstein College Of Medicine, Inc. Aptamer-targetted antigen delivery
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI775117B (zh) 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
JP6985153B2 (ja) 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
PH12018501893A1 (en) 2015-08-28 2022-05-02 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments

Also Published As

Publication number Publication date
KR102493344B1 (ko) 2023-01-30
US20190055302A1 (en) 2019-02-21
SG10202008070XA (en) 2020-10-29
US20250145686A1 (en) 2025-05-08
US20190055301A1 (en) 2019-02-21
MA43466A1 (fr) 2020-05-29
CL2020001897A1 (es) 2020-10-02
PH12022551120A1 (en) 2023-03-06
TWI771694B (zh) 2022-07-21
EP4491191A3 (en) 2025-04-09
US10669325B2 (en) 2020-06-02
MX2022003884A (es) 2022-06-14
TWI731945B (zh) 2021-07-01
US12221467B2 (en) 2025-02-11
PH12018501828A1 (en) 2019-07-08
US20210300968A1 (en) 2021-09-30
IL261468A (en) 2018-10-31
US20210309715A1 (en) 2021-10-07
SG11201807300PA (en) 2018-09-27
KR20230019501A (ko) 2023-02-08
US10138287B2 (en) 2018-11-27
CN118894905A (zh) 2024-11-05
TW202043264A (zh) 2020-12-01
CR20210036A (es) 2021-02-18
MA49295A (fr) 2019-01-16
CL2018002508A1 (es) 2018-10-26
TW201738274A (zh) 2017-11-01
US11390660B2 (en) 2022-07-19
JP2019511214A (ja) 2019-04-25
US20190023763A1 (en) 2019-01-24
BR112018015545A2 (pt) 2018-12-26
PE20181490A1 (es) 2018-09-18
AR108035A1 (es) 2018-07-11
MX2018010779A (es) 2019-05-22
WO2017153247A1 (en) 2017-09-14
EP3426281A1 (en) 2019-01-16
AU2017229149B2 (en) 2021-09-16
AU2021207620A1 (en) 2021-08-19
ES3005964T3 (en) 2025-03-17
MY189796A (en) 2022-03-08
US20190194289A1 (en) 2019-06-27
CA3015932A1 (en) 2017-09-14
US20170260249A1 (en) 2017-09-14
CL2020001898A1 (es) 2020-10-02
KR20180116417A (ko) 2018-10-24
CO2018010284A2 (es) 2018-10-10
AU2017229149A1 (en) 2018-10-25
EA201891994A1 (ru) 2019-02-28
CN109475596B (zh) 2024-06-28
US10266581B2 (en) 2019-04-23
JP2023093483A (ja) 2023-07-04
US12234276B2 (en) 2025-02-25
US10239932B2 (en) 2019-03-26
EP3426281B1 (en) 2024-11-20
US20200071379A1 (en) 2020-03-05
EP4491191A2 (en) 2025-01-15
CR20180460A (es) 2018-12-06
CN109475596A (zh) 2019-03-15
CR20210038A (es) 2021-02-16

Similar Documents

Publication Publication Date Title
IL261468A (en) Uterine cancer treatments
IL271946A (en) Combination for cancer treatment
IL254705B (en) Combined treatment for cancer
IL263123A (en) Cancer treatments
LT3197456T (lt) Vėžio gydymas
SI3423087T1 (sl) Kombinirana terapija proti raku
PT3576740T (pt) Tratamento de cancro
SG10202105110VA (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL247859A0 (en) Cancer treatment
IL274626A (en) Cancer treatment
IL260814A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
GB2546773B (en) Cancer
GB201522433D0 (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201704909D0 (en) Cancer therapy
IL259097A (en) Combination therapy for cancer
GB201711855D0 (en) Cancer therapy
GB201720533D0 (en) Cancer treatments
HK40002238A (en) Uterine cancer treatments
GB201514777D0 (en) Cancer Treatments
GB201713852D0 (en) Cancer treatment
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)